Cytori Therapeutics
Cytori Therapeutics is a San Diego-based biotechnology company developing autologous cell therapies using adipose-derived regenerative cells. It markets the Celution System platform and related devices to healthcare providers and researchers globally through regional distribution partners and direct sales.
- Company typePublic
- Founded1996
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cytori Therapeutics does
Cytori Therapeutics is a San Diego-based biotechnology company founded in 1996 that develops autologous cell therapies using Adipose-Derived Regenerative Cells (ADRCs) extracted from a patient's own adipose tissue. Its core technology is the Celution System, a proprietary medical device platform that automates and standardizes the extraction, washing, and concentration of clinical-grade ADRCs at the point of care within a single surgical procedure. The platform is complemented by Celase GMP (a proprietary blended proteolytic enzyme for tissue dissociation), the Celbrush surgical instrument for precise fat-tissue micro-droplet delivery, and the StemSource 900/MB Tissue Processor with associated Cell Bank service plans, providing a GTP-compliant cryopreservation workflow. Cytori's intellectual property position rests on a portfolio of 100 issued patents worldwide and an evidence base of multiple peer-reviewed clinical trials (RESTORE-2, STAR, Athena) across cardiology, scleroderma, wound healing, and reconstructive surgery.
Cytori Therapeutics firmographics
Firmographics- Name
- Cytori Therapeutics
- Legal name
- Cytori Therapeutics, Inc.
- Website
- https://cytori.com
- Company type
- Public
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cytori Therapeutics is a San Diego-based biotechnology company developing autologous cell therapies using adipose-derived regenerative cells. It markets the Celution System platform and related devices to healthcare providers and researchers globally through regional distribution partners and direct sales.
- Ownership category
- akta.pro rank
Cytori Therapeutics industry classification
Industry- Product category
- Regenerative Medicine Medical Devices
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industries
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)
Keywords
Where Cytori Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Cytori Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Revenue model
- Medical Devices and Equipment: Sale and lease of proprietary medical devices including the Celution 800 CRS and 800 IV systems, StemSource tissue processing equipment, and Celase GMP enzyme products for research and clinical applications.
- Product Support Plans: Annual support plans covering technical support, preventative maintenance, repairs, and training for Celution products. Includes unlimited remote technical support 24/7 and annual onsite comprehensive visits.
- Surgical Instruments: Sale of Celbrush surgical instruments for precise tissue delivery, available in 3mL and 10mL configurations with starter kit options.
- StemSource Bank Services: Service plans for StemSource Cell Bank including 1-Year and 3-Year Bank Service Plans for tissue processing and cryopreservation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard product pricing with volume-specific quotes |
Go-to-market motion1 record
Distribution channels8 records
Marketing channels5 records
Cytori Therapeutics product offering
Product offeringCore offering
Cytori Therapeutics develops and commercializes cell therapy products and medical devices centered on the proprietary Celution System platform, which automates the extraction and concentration of Adipose-Derived Regenerative Cells (ADRCs) from a patient's own adipose tissue for autologous reimplantation within a single surgical procedure. The portfolio includes medical devices (Celution 800 CRS and 800 IV systems), procedure sets, the Celase GMP proteolytic enzyme, Celbrush surgical instruments, and the StemSource Cell Bank for cryopreservation of ADRCs. The company also offers Habeo Cell Therapy, an investigational autologous cell therapy for hand manifestations of systemic scleroderma available through Early Access Programs.
Product overview
Cytori Therapeutics develops and commercializes cell therapy products and medical devices centered on Adipose-Derived Regenerative Cells (ADRCs). The core product line includes the Celution System (Celution 800 CRS Device with 820 CRS Procedure Set, and Celution 800 IV Device with 860 IV Procedure Set) for automated extraction and concentration of ADRCs at point-of-care, supported by Celase GMP proteolytic enzyme for tissue dissociation and Celbrush surgical instruments for precise delivery. The StemSource Cell Bank family provides tissue processing equipment (900/MB Tissue Processor), procedure sets, and service plans for cryopreservation of ADRCs. Cytori Cell Therapy represents the therapeutic application of these technologies for treating conditions including scleroderma, wounds, and soft tissue reconstruction, with Habeo Cell Therapy available through Early Access Programs. The company serves healthcare providers across Americas, Asia Pacific, and Europe through regional distribution partners.
Differentiator
Problem solved
Functional benefit
Brands
- Cytori Cell Therapy: Collective name for the fresh, heterogeneous population of ADRCs prepared with the proprietary Celution System platform technology.
- Celution
- Habeo Cell Therapy
- Celase GMP
- Celbrush
- StemSource
Products and services
- Celution 800 CRS Device
Quantifiable outcome
- Frequency of stem cells in adipose tissue shown to be 2,500 times greater than in bone marrow
- +1 more outcomes
Companies that use Cytori Therapeutics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Cytori Therapeutics technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Cytori Therapeutics partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and regional.
- myTomorrowscoremyTomorrows serves as Cytori's Early Access Program distributor across the EU, Middle East and Latin America (excluding Chile), providing patients with hand manifestations of systemic scleroderma access to Habeo Cell Therapy.
- Worthington Biochemical CorporationcoreWorthington Biochemical Corporation serves as a distribution partner for Celase GMP and products in countries not covered by other regional distributors.
- Lorem VascularcoreLorem Vascular is an authorized distribution partner covering Australia, China, Hong Kong, Malaysia, and Singapore markets for Cytori products.
- Inamed Medical Equipment Co LtdregionalAuthorized distributor for Vietnam only.
- Integrated Bio LtdregionalAuthorized distributor for Taiwan only.
- CHAYON Laboratories, Inc.regionalAuthorized distributor for Korea only.
- CogenregionalAuthorized distributor for Korea only.
- Karam MedicalregionalAuthorized distributor for Celbrush in Spain only.
- SURE MedicalregionalAuthorized distributor for Celbrush in Netherlands only.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Cytori Therapeutics competitors and assessment
Company assessmentBroad incumbents
- MiMedx Group: MiMedx develops and commercializes placental tissue allografts (EpiFix, AmnioFix) for wound care and surgical applications. Competes in adjacent regenerative medicine space, particularly for wound healing and soft tissue repair indications that overlap with Cytori's applications.
- Organogenesis Holdings: Organogenesis is a commercial-stage regenerative medicine company with wound care and surgical biologics portfolios (Apligraf, Dermagraft, PuraPly). A broader incumbent in regenerative medicine with overlapping wound healing and surgical reconstruction indications that Cytori addresses with ADRCs.
Direct peers
- Lineage Cell Therapeutics: Lineage develops allogeneic cell therapies for ophthalmology, oncology, and CNS indications. A direct cell therapy competitor with overlapping regenerative medicine positioning and similar hospital/research channel distribution.
- Athersys Inc. Athersys develops MultiStem cell therapy for stroke, ARDS, and inflammatory conditions. Operates as a clinical-stage cell therapy peer targeting similar hospital-administered, regenerative medicine use cases as Cytori.
- Mesoblast Limited: Mesoblast develops cellular medicines for inflammatory and cardiovascular diseases (e.g., remestemcel-L, Rexlemestrocel-L). Targets overlapping indications (cardiovascular disease, inflammatory conditions) with cell therapy approaches, making it a direct competitor in physician-administered regenerative medicine.
- BrainStorm Cell Therapeutics: BrainStorm develops autologous cell therapies (NurOwn) for neurodegenerative diseases. Comparable as a clinical-stage autologous cell therapy developer with platform technology and hospital-administered treatment model.
- Vericel Corporation: Vericel develops autologous cell therapies (MACI for cartilage repair, NexoBrid for burns) sold through specialty distribution. Most directly comparable to Cytori in autologous cell therapy commercialization model, hospital channel, and surgical workflow focus.
- Pluristem Therapeutics: Pluristem develops allogeneic placental cell therapies for hematological, vascular, and inflammatory indications. Competes in the regenerative cell therapy space with a contrasting allogeneic manufacturing model versus Cytori's autologous platform.
Emerging players
- Caladrius Biosciences: Caladrius is developing cell therapies for autoimmune and inflammatory indications (CLBS03, CLBS14). Emerging peer with overlapping cell therapy mechanism and clinical-stage positioning, though focused on different therapeutic areas than Cytori.
- Capricor Therapeutics: Capricor develops cell-derived therapies (CAP-1002 for Duchenne muscular dystrophy and COVID-19 long-haul). Emerging cell therapy peer addressing similar rare disease and inflammatory indications where autologous or cell-based interventions are reimbursed.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
Cytori Therapeutics social profiles
Digital presenceCytori Therapeutics compliance and trust
Trust signalCompliance4 records
Cytori Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cytori Therapeutics leadership team
Management profileNumber of profiles
Cytori Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries3 records
Cytori Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cytori Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cytori Therapeutics
What does Cytori Therapeutics do?
Cytori Therapeutics develops and commercializes cell therapy products and medical devices centered on the proprietary Celution System platform, which automates the extraction and concentration of Adipose-Derived Regenerative Cells (ADRCs) from a patient's own adipose tissue for autologous reimplantation within a single surgical procedure. The portfolio includes medical devices (Celution 800 CRS and 800 IV systems), procedure sets, the Celase GMP proteolytic enzyme, Celbrush surgical instruments, and the StemSource Cell Bank for cryopreservation of ADRCs. The company also offers Habeo Cell Therapy, an investigational autologous cell therapy for hand manifestations of systemic scleroderma available through Early Access Programs.
Is Cytori Therapeutics a public or private company?
Cytori Therapeutics is a public company. It is classified as public and is currently operating.
When was Cytori Therapeutics founded?
Cytori Therapeutics was founded in 1996. It employs 51 to 100 people.
Where is Cytori Therapeutics based?
Cytori Therapeutics is headquartered in San Diego, United States, in the North America region.
How does Cytori Therapeutics make money?
Four revenue lines are on record. Medical Devices and Equipment is the primary driver. The others are product Support Plans, surgical Instruments and stemSource Bank Services.
Who are Cytori Therapeutics's main competitors?
Broad incumbents on record are MiMedx Group and Organogenesis Holdings. Direct peers are Lineage Cell Therapeutics, Athersys Inc., Mesoblast Limited, BrainStorm Cell Therapeutics, Vericel Corporation and Pluristem Therapeutics. Emerging players are Caladrius Biosciences and Capricor Therapeutics.
Does Cytori Therapeutics have an API?
No public API is recorded for Cytori Therapeutics.
What industry is Cytori Therapeutics in?
Cytori Therapeutics's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 325414 and its SIC code is 3841.